Breakthrough disease during interferon-[beta] therapy in MS: No signs of impaired biologic response

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

Breakthrough disease during interferon-[beta] therapy in MS: No signs of impaired biologic response. / Hesse, D; Krakauer, M; Lund, H; Søndergaard, H B; Langkilde, A; Ryder, L P; Sørensen, Per Soelberg; Sellebjerg, F; Langkilde, Annika.

I: Neurology, Bind 74, Nr. 18, 04.05.2010, s. 1455-62.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Hesse, D, Krakauer, M, Lund, H, Søndergaard, HB, Langkilde, A, Ryder, LP, Sørensen, PS, Sellebjerg, F & Langkilde, A 2010, 'Breakthrough disease during interferon-[beta] therapy in MS: No signs of impaired biologic response', Neurology, bind 74, nr. 18, s. 1455-62. https://doi.org/10.1212/WNL.0b013e3181dc1a94

APA

Hesse, D., Krakauer, M., Lund, H., Søndergaard, H. B., Langkilde, A., Ryder, L. P., Sørensen, P. S., Sellebjerg, F., & Langkilde, A. (2010). Breakthrough disease during interferon-[beta] therapy in MS: No signs of impaired biologic response. Neurology, 74(18), 1455-62. https://doi.org/10.1212/WNL.0b013e3181dc1a94

Vancouver

Hesse D, Krakauer M, Lund H, Søndergaard HB, Langkilde A, Ryder LP o.a. Breakthrough disease during interferon-[beta] therapy in MS: No signs of impaired biologic response. Neurology. 2010 maj 4;74(18):1455-62. https://doi.org/10.1212/WNL.0b013e3181dc1a94

Author

Hesse, D ; Krakauer, M ; Lund, H ; Søndergaard, H B ; Langkilde, A ; Ryder, L P ; Sørensen, Per Soelberg ; Sellebjerg, F ; Langkilde, Annika. / Breakthrough disease during interferon-[beta] therapy in MS: No signs of impaired biologic response. I: Neurology. 2010 ; Bind 74, Nr. 18. s. 1455-62.

Bibtex

@article{8af84f5a38de4f1e8bba1626ddf21def,
title = "Breakthrough disease during interferon-[beta] therapy in MS: No signs of impaired biologic response",
abstract = "Disease activity is highly variable in patients with multiple sclerosis (MS), both untreated and during interferon (IFN)-beta therapy. Breakthrough disease is often regarded as treatment failure; however, apart from neutralizing antibodies (NAbs), no blood biomarkers have been established as reliable indicators of treatment response, despite substantial, biologically measurable effects. We studied the biologic response to treatment in a cohort of NAb-negative patients to test whether difference in responsiveness could segregate patients with and without breakthrough disease during therapy.",
author = "D Hesse and M Krakauer and H Lund and S{\o}ndergaard, {H B} and A Langkilde and Ryder, {L P} and S{\o}rensen, {Per Soelberg} and F Sellebjerg and Annika Langkilde",
year = "2010",
month = may,
day = "4",
doi = "http://dx.doi.org/10.1212/WNL.0b013e3181dc1a94",
language = "English",
volume = "74",
pages = "1455--62",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams & Wilkins",
number = "18",

}

RIS

TY - JOUR

T1 - Breakthrough disease during interferon-[beta] therapy in MS: No signs of impaired biologic response

AU - Hesse, D

AU - Krakauer, M

AU - Lund, H

AU - Søndergaard, H B

AU - Langkilde, A

AU - Ryder, L P

AU - Sørensen, Per Soelberg

AU - Sellebjerg, F

AU - Langkilde, Annika

PY - 2010/5/4

Y1 - 2010/5/4

N2 - Disease activity is highly variable in patients with multiple sclerosis (MS), both untreated and during interferon (IFN)-beta therapy. Breakthrough disease is often regarded as treatment failure; however, apart from neutralizing antibodies (NAbs), no blood biomarkers have been established as reliable indicators of treatment response, despite substantial, biologically measurable effects. We studied the biologic response to treatment in a cohort of NAb-negative patients to test whether difference in responsiveness could segregate patients with and without breakthrough disease during therapy.

AB - Disease activity is highly variable in patients with multiple sclerosis (MS), both untreated and during interferon (IFN)-beta therapy. Breakthrough disease is often regarded as treatment failure; however, apart from neutralizing antibodies (NAbs), no blood biomarkers have been established as reliable indicators of treatment response, despite substantial, biologically measurable effects. We studied the biologic response to treatment in a cohort of NAb-negative patients to test whether difference in responsiveness could segregate patients with and without breakthrough disease during therapy.

U2 - http://dx.doi.org/10.1212/WNL.0b013e3181dc1a94

DO - http://dx.doi.org/10.1212/WNL.0b013e3181dc1a94

M3 - Journal article

VL - 74

SP - 1455

EP - 1462

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 18

ER -

ID: 34078810